Lymphoma | Topics

 
Real-World Data Suggest Systemic High-Dose and Intrathecal MTX Lower CNS Relapse Incidence for DLBCL
May 07, 2021

The 3-year follow-up analysis of 4 treatment groups who received CNS prophylaxis found a decreased incidence of CNS relapse for patients with high-risk diffuse large B-cell lymphoma, although the data were not statistically significant.

Matthew J. Matasar, MD, on the Clinical Implications of the Phase 3 CHRONOS-3 Study
April 27, 2021

The lymphoma expert discussed how adding copanlisib to rituximab improved progression-free survival, while demonstrating a manageable safety profile in patients with relapsed indolent non-Hodgkin lymphoma.

Matthew J. Matasar, MD, Discusses ‘Breadth of Scientific Investigation’ at AACR Annual Meeting
April 23, 2021

The lymphoma expert offered highlights from the meeting, with hopes that more treatment options will be available for patients with lymphoma.